Relmada Therapeutics, Inc. (RLMD): who owns it and who trades it
As of Nov 16, 2026, RLMD insiders reported 6 purchases worth $1.8M in the last 12 months. The largest buyer was Sergio Traversa (CEO), with $941K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Relmada Therapeutics
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RLMD
126 funds and institutions reported RLMD shares worth $696M at the end of Q2 2026, about 96% of the company. The largest holder is Jupiter Topco LLC with 10.6%.
Funds and institutions (13F) 96%Everyone else 4%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.16M | 10.64% | $77.3M | – |
| BlackRock, Inc. | 7.43M | 7.08% | $51.4M | +476% |
| Squadron Capital Management LLC | 7.35M | 7.01% | $50.9M | -13% |
| Venrock Adviser, LLC | 6.84M | 6.53% | $47.4M | +41% |
| Spruce Street Capital LP | 6.39M | 6.09% | $44.2M | +2% |
| Adage Capital Partners Gp, L.l.c. | 4.76M | 4.54% | $33M | No change |
| Vanguard Capital Management LLC | 4.46M | 4.25% | $30.9M | +45% |
| Jones Hill Capital LP | 3.66M | 3.48% | $25.3M | +966% |
| Orbimed Advisors LLC | 3.63M | 3.46% | $25.1M | -23% |
| State Street Corp | 2.52M | 2.40% | $17.4M | +605% |
| Geode Capital Management, LLC | 2.49M | 2.38% | $17.3M | +194% |
| Millennium Management LLC | 2.36M | 2.25% | $16.3M | -40% |
| Marshall Wace, LLP | 2.25M | 2.14% | $15.5M | -50% |
| Ikarian Capital, LLC | 2.15M | 2.05% | $14.9M | -20% |
| Driehaus Capital Management LLC | 2.13M | 2.03% | $14.8M | No change |
| Ameriprise Financial Inc | 1.94M | 1.85% | $13.4M | +263% |
| Eventide Asset Management, LLC | 1.86M | 1.77% | $12.9M | +121% |
| Balyasny Asset Management L.P. | 1.52M | 1.45% | $10.5M | +502% |
| Stempoint Capital LP | 1.46M | 1.39% | $10.1M | +22% |
| Commodore Capital LP | 1.43M | 1.36% | $9.9M | +125% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RLMD insiders reported $1.8M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Maged Shenouda | CFO | Purchase | 79,800 | $4.25 | $339K | Form 4 |
| Sep 10, 2026 | Sergio Traversa | CEO | Purchase | 100,000 | $4.10 | $410K | Form 4 |
| Sep 9, 2026 | Maged Shenouda | CFO | Purchase | 120,200 | $4.20 | $505K | Form 4 |
| Sep 9, 2026 | Sergio Traversa | CEO | Purchase | 100,000 | $4.18 | $418K | Form 4 |
| Dec 15, 2025 | Sergio Traversa | CEO | Purchase | 27,500 | $4.12 | $113K | Form 4 |
| Dec 15, 2025 | Maged Shenouda | CFO | Purchase | 11,665 | $4.12 | $48.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | $941K | – | Sep 10, 2026 |
| Maged Shenouda | Chief Financial Officer | $892K | – | Sep 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RLMD short interest
High short interest. 10.2% of RLMD shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 98%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.84M RLMD shares were sold short, 10.2% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 1.70M shares, buying them all back would take about 6.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.84M | 10.16% | -11% | 1.70M | 6.4 |
| Oct 15, 2026 | 12.18M | 11.42% | -9% | 1.43M | 8.5 |
| Sep 30, 2026 | 13.42M | 12.58% | -7% | 1.03M | 13.0 |
| Sep 15, 2026 | 14.46M | 13.56% | +6% | 1.56M | 9.2 |
| Aug 31, 2026 | 13.60M | 12.75% | +5% | 768,191 | 17.7 |
| Aug 14, 2026 | 12.89M | 12.09% | -5% | 1.38M | 9.3 |
| Jul 31, 2026 | 13.56M | 12.93% | +4% | 1.74M | 7.8 |
| Jul 15, 2026 | 12.99M | 12.38% | +22% | 1.54M | 8.5 |
| Jun 30, 2026 | 10.65M | 10.15% | +76% | 3.47M | 3.1 |
| Jun 15, 2026 | 6.06M | 5.78% | +4% | 1.37M | 4.4 |
| May 29, 2026 | 5.84M | 5.57% | +6% | 961,523 | 6.1 |
| May 15, 2026 | 5.49M | 5.23% | +3% | 898,231 | 6.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Relmada Therapeutics company events
Relmada Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 8, 2026.
- Sep 8, 2026AnnouncementDr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 28, 2026AnnouncementShared information with investors. Filing
- May 28, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 20, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AgreementRelmada Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Filing
- Dec 15, 2025LeadershipThe Board of Directors the Board of Directors of Relmada Therapeutics, Inc. approved an amended and restated employment agreement with each of its executive officers, each to become effective as of January 1, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Relmada Therapeutics financials
Famous investors that hold RLMD
3 of the 50 well-known investors we track reported holding RLMD in their latest 13F filing. The largest position is Israel Englander's, worth $12.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.35M | $12.6M | 0.0% | +42% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 503,192 | $1.9M | 0.0% | +771% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 442,103 | $1.7M | 0.0% | -58% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RLMD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 3.3% |
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 3.3% |
Questions about Relmada Therapeutics, Inc. (RLMD) stock
Who owns the most RLMD stock?
The largest reported owner of Relmada Therapeutics, Inc. (RLMD) is Jupiter Topco LLC, with 10.6% of the company. In total, 126 funds and institutions reported holding RLMD at the end of Q2 2026, together about 96% of the shares. See the largest owners.
Are RLMD insiders buying or selling?
In the last 12 months, RLMD insiders reported 6 open-market purchases worth $1.8M and no sales. The latest trade was on Sep 10, 2026. See every trade.
What is the short interest in RLMD?
As of Oct 30, 2026, 10.84M RLMD shares were sold short, 10.2% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 1.70M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.
Which famous investors hold RLMD?
3 of the 50 well-known investors we track reported RLMD in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $12.6M. See all holders.
Executive pay
Relmada Therapeutics's chief executive was paid a total of $8.9M for the year ended Dec 31, 2025, up 394% from $1.8M the year before. In the last 12 months, Relmada Therapeutics's executives and directors bought $1.8M of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.